Compare DoorDash Inc (DASH) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Neurocrine Biosciences Inc — how do they compare? DoorDash Inc trades at $195.87 (market cap $83.07B), while Neurocrine Biosciences Inc trades at $142.45 (market cap $14.36B). The key difference: DoorDash Inc is far larger — about 5.8× Neurocrine Biosciences Inc's market cap, and DoorDash Inc is more actively traded (3,242,567 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Neurocrine Biosciences Inc for 23 Days on average.
| DASH | NBIX | |
|---|---|---|
Market Cap | $83.07B | $14.36B |
Volume | 3,242,567 | 1,237,180 |
Sector | Media | Health |
52-Week High | $275.44 | $185.50 |
52-Week Low | $146.60 | $123.10 |
Typical Hold Time | 59 Days | 23 Days |
Enterprise Value | $81.03B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $196.33, up 2.66% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent developments include AI-powered text ordering and drone delivery expansion. Analyst consensus remains strongly bullish with 75% buy ratings and a $255.80 price target, representing 30% upside potential from current levels.
The outlook remains positive with continued revenue growth projected to $15.9B in 2026, though net income may moderate to $841M. Key risks include competitive pressures, regulatory scrutiny from ongoing investigations, and execution challenges in new initiatives. The stock trades at premium valuations (P/E 100.37) requiring sustained growth to justify current levels.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
